Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test.
Pujadas E, Ibeh N, Hernandez MM, Waluszko A, Sidorenko T, Flores V, Shiffrin B, Chiu N, Young-Francois A, Nowak MD, Paniz-Mondolfi AE, Sordillo EM, Cordon-Cardo C, Houldsworth J, Gitman MR. Pujadas E, et al. Among authors: sidorenko t. J Med Virol. 2020 Sep;92(9):1695-1698. doi: 10.1002/jmv.25988. Epub 2020 May 22. J Med Virol. 2020. PMID: 32383179 Free PMC article.
Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment.
Tervonen T, Fox RJ, Brooks A, Sidorenko T, Boyanova N, Levitan B, Hennessy B, Phillips-Beyer A. Tervonen T, et al. Among authors: sidorenko t. Mult Scler J Exp Transl Clin. 2023 Jan 23;9(1):20552173221150370. doi: 10.1177/20552173221150370. eCollection 2023 Jan-Mar. Mult Scler J Exp Transl Clin. 2023. PMID: 36714174 Free PMC article.
An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis.
Valenzuela B, Olsson Gisleskog P, Poggesi I, Sidorenko T, Burcklen M, Kracker H, Pérez-Ruixo JJ. Valenzuela B, et al. Among authors: sidorenko t. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1294-1304. doi: 10.1002/psp4.12778. Epub 2022 Sep 1. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 36047474 Free PMC article. Clinical Trial.
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies.
Freedman MS, Pozzilli C, Havrdova EK, Lemle A, Burcklen M, Larbalestier A, Hennessy B, Sidorenko T, Vaclavkova A, Olsson T; Ponesimod Phase II Study Group. Freedman MS, et al. Among authors: sidorenko t. Neurology. 2022 Aug 23;99(8):e762-e774. doi: 10.1212/WNL.0000000000200606. Epub 2022 Jun 6. Neurology. 2022. PMID: 35667837 Free PMC article. Clinical Trial.
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Olsson T, Boster A, Fernández Ó, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M. Olsson T, et al. Among authors: sidorenko t. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1198-208. doi: 10.1136/jnnp-2013-307282. Epub 2014 Mar 21. J Neurol Neurosurg Psychiatry. 2014. PMID: 24659797 Free PMC article. Clinical Trial.
27 results